• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, August 7, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

A bacteria likely to reduce the cardiovascular risks of 1 in 2 people

Bioengineer by Bioengineer
July 1, 2019
in Health
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

University of Louvain research in world premiere

IMAGE

Credit: Patrice Cani, UCLouvain

In 2007, Patrice Cani (FNRS-WELBIO researcher) and his team at the Louvain Drug Research Institute of University of Louvain, in close collaboration with Willem de Vos, professor at UWageningen, discovered the beneficial effects of an intestinal bacteria, Akkermansia muciniphila (1), able to moderate the development of obesity and type 2 diabetes, in mice. In 2017, the team discovered (still in the mouse) that the use of a pasteurized form of Akkermansia leads to an even greater protection than the living bacterium regarding various cardiovascular disease risk factors such as insulin resistance, hypercholesterolemia, or the storage of fat in adipose tissue.

Following these discoveries, the UCLouvain team, in collaboration with the Cliniques universitaires Saint-Luc (2), developed a clinical study in order to administer the bacteria to humans. For this, it was necessary to develop the capacity to produce the bacterium in large quantity and to make sure that the tests would be without risk for the participants.

The UCLouvain researchers administered Akkermansia to overweight or obese volunteers, all displaying insulin resistance (pre-diabetes type 2) and metabolic syndrome, in other words, having several elevated risk factors for cardiovascular diseases. The volunteers were randomly divided into 3 groups (placebo, live bacteria and pasteurized bacteria) and were asked not to change their dietary habits or their physical activity. Akkermansia was provided as a nutritional supplement.

The primary goal of this UCLouvain study was to demonstrate the feasibility of daily ingesting Akkermansia for 3 months, without risk. Clara Depommier and Amandine Everard, UCLouvain researchers, observed excellent compliance (the supplements were easy to ingest) and tolerance (there were no side effects) in the groups taking live or pasteurized bacteria.

The conclusions are clear: the tests in humans confirm what had already been observed in mice. Ingestion of the (pasteurized) bacterium prevented the deterioration of the health status of the subjects (pre-diabetes, cardiovascular risks). Even better, the researchers observed a decrease in inflammation markers in the liver, a slight decrease in the body weight of the subjects (2.3 kg on average (3)) as well as a lowering of cholesterol levels. In contrast, the metabolic parameters (insulin resistance or hypercholesterolemia) in placebo subjects continued to deteriorate over time.

Who does it benefit? According to the WHO, one in three people die every day from cardiovascular disease worldwide. In Western countries, one in two people is overweight and has increased cardiovascular risks. This research of the UCLouvain would limit these risks and therefore potentially have an impact (limit the effects) on half of the population, if properly used.

In conclusion, this pilot study demonstrates the feasibility of administrating (pasteurized) Akkermansia bacteria to humans in the form of a food supplement and reports encouraging results on the effectiveness of the Akkermansia-based dietary supplements to reduce cardio-metabolic risk factors. These results pave the way for a large-scale study, to confirm/elaborate these first results, but also endorse the commercialization of the bacteria as food supplements, by 2021.

###

A generic email address has been created for the public who wants more information about the current clinical study: [email protected].

To carry out this research, Patrice Cani has benefited from several fundings, via the FNRS (Belgian Research National Funds), the EOS (EU Excellence of Science), the Funds Baillet-Latour, the WELBIO, the Bank Transatlantic Belgium, the Walloon Region (DGO6) and two European ERC grants (starting and proof of concept).

How to communicate about this research? It’s in the details.

  • Food supplement or probiotic?
    • CORRECT: food supplement = concentrated source of nutrients intended to correct nutritional deficiencies of a person’s regular diet
    • INCORRECT: probiotic = living microorganism which, when consumed in adequate quantities, brings a health benefit to the human being. To be called probiotic, a product must have been the subject of many studies in humans. As of yet, no bacteria (or product) sold on the European market may be referred to as a probiotic.
      • the bacteria Akkermansia is not a probiotic
  • Limit or treat risk factors?
    • CORRECT: Limit: “Limit the increase of risk factors” applies to food supplements
      • Akkermansia limits cardiovascular risk factors
    • INCORRECT: treat: treatments only apply to drugs
      • the clinical tests were not carried out with drugs but with a food supplement
  • Study or clinical trials?
    • CORRECT: UCLouvain and the Cliniques universitaires Saint-Luc have conducted a clinical study with dietary supplements
    • INCORRECT: clinical trials refer to the administration of a drug/treatment.
  • Volunteer or patient?
    • CORRECT: volunteer = person made a conscious decision to enroll in a clinical study
    • INCORRECT: patient = person under treatment
      • the UCLouvain researchers have not tested any treatment

(1)Bacteria naturally present in large quantities in healthy people

(2)Prof. Jean-Paul Thissen, Prof. Michel Hermans, Prof. Dominique Maiter, Dr. Audrey Loumaye

(3)These results are statistically considered non-significant. That said, according to the precise analysis of the different intestinal bacteria (in collaboration with the team of Prof. Raes of the KULeuven), the observed effects are independent of a general modification of the microbiota and therefore probably specific to the action of Akkermansia.

Media Contact
Sébastien Berg
[email protected]

Original Source

https://uclouvain.be/en/discover/press/news/a-bacteria-likely-to-reduce-the-cardiovascular-risks-of-1-in-2-people.html

Related Journal Article

http://dx.doi.org/10.1038/s41591-019-0495-2

Tags: AddictionCholesterolClinical TrialsDiabetesDiet/Body WeightEating Disorders/ObesityMedicine/HealthMetabolism/Metabolic DiseasesNutrition/Nutrients
Share12Tweet8Share2ShareShareShare2

Related Posts

Multi-Omics Uncovers T-Cell Exhaustion and Galectin-9 Target

Multi-Omics Uncovers T-Cell Exhaustion and Galectin-9 Target

August 7, 2025
blank

Adolescent Psychedelic Use Linked to Personality Traits

August 7, 2025

Opioid-Sparing Strategies for Children’s Perioperative Pain

August 7, 2025

Estimating Population Affinity in South African Forensics

August 7, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    76 shares
    Share 30 Tweet 19
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    44 shares
    Share 18 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

IL22RA1 Expression Predicts Colon Cancer Progression

Microglia Control Prenatal GABAergic Neurogenesis via IGF1

Multi-Omics Uncovers T-Cell Exhaustion and Galectin-9 Target

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.